Medtronic plc, a leader in medical technology, has announced receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Visualase™ V2 MRI-Guided Laser Ablation System. This clearance marks a significant advancement in the Visualase™ platform, enhancing its capabilities as a minimally invasive surgical option for treating conditions such as focal epilepsy, brain tumors, and radiation necrosis. With redesigned software and hardware, the V2 system offers improved precision, accuracy, and visualization, allowing for efficient workflows and real-time MRI guidance. This innovation promises reduced hospital stays, faster recovery, minimal scarring, lower infection risks, and high patient satisfaction.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.